Clicky

Opko Health Inc(OPK)

Description: OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.


Keywords: Pharmaceutical Products Disease Diabetes Antibiotics Obesity Chronic Kidney Disease Food Supplements Ophthalmic Products Counter Products Cardiovascular Products Laboratory Testing Services Secondary Hyperparathyroidism Opko Health Gastro Intestinal Products

Home Page: www.opko.com

4400 Biscayne Boulevard
Miami, FL 33137
United States
Phone: 305 575 4100


Officers

Name Title
Dr. Phillip Frost Ph.D. Chairman & CEO
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D. Vice Chairman & Chief Technical Officer
Mr. Adam E. Logal Sr. VP, CFO, Chief Accounting Officer & Treasurer
Mr. Steven D. Rubin Esq., J.D. Exec. VP of Admin. & Director
Dr. Jon R. Cohen M.D. Advisor
Dr. Elias Adam Zerhouni M.D. Pres & Vice Chairman
Dr. Arie Gutman Pres of API
Mr. James DeMarco Sr. VP of Pharmaceutical Sales
Dr. Akhtar Ashfaq Sr. VP of Clinical R&D and Medical Affairs
Ms. Jane Pine Wood Esq., J.D. Chief Legal Officer of Bio-Reference Laboratories

Exchange: TA

Country: IL

Currency: Israeli Agora (ILA)

Forward PE: 66.2252
Trailing PE: 0
Price-to-Book MRQ: 0.63
Price-to-Sales TTM: 2.7781
IPO Date:
Fiscal Year End: December
Full Time Employees: 5767
Back to stocks